www.ngmbio.com Open in urlscan Pro
35.190.165.113  Public Scan

Form analysis
0 forms found in the DOM

Text Content

We're Hiring!

icon / arrow

linked in
instagram
twitter
Fill 1


 * 01 HOME
   
   


 * 02 ABOUT NGM
   
   
   PARTNERSHIP OPPORTUNITIES


 * 03 DISCOVERY ENGINE
   
   
   ONCOLOGY
   
   RETINAL DISEASE
   
   LIVER & METABOLIC DISEASE
   
   PUBLICATIONS


 * 04 PIPELINE
   
   


 * 05 TEAM
   
   


 * 06 INVESTORS & MEDIA
   
   


 * 07 CAREERS
   
   


 * 08 CONTACT
   
   



EXPLORERS ON THE FRONTIER OF

LIFE-CHANGING SCIENCE.

At NGM, we are charting new paths and pushing beyond boundaries to discover and
deliver medicines for people whose health and lives have been disrupted by
disease.

icon / arrow

SCROLL TO DISCOVER


JUNE 30, 2022

32 Questions at NGM Bio with President, Siobhan Nolan Mangini and CEO, David
Woodhouse

icon / arrow diagonal

Our mission is to translate complex, powerful biology with rigor and urgency
into life-changing medicines.

Our vision is to make lasting scientific contributions that improve human life.


icon / arrow
Learn More


LATEST NGM BIO NEWS




OUR PIPELINE

WE ARE ADVANCING OUR BROAD AND DIVERSE PIPELINE OF BIOLOGIC DRUG CANDIDATES, ALL
DISCOVERED IN-HOUSE, WITH THE GOAL OF ADDRESSING LARGE UNMET MEDICAL NEEDS IN
CANCER AND OTHER DISEASES THAT IMPACT THE LIVES OF MILLIONS AROUND THE WORLD.

View Full Pipeline
icon / →


ONCOLOGY

MYELOID REPROGRAMMING AND CHECKPOINT INHIBITION PORTFOLIO

NGM707
NGM707

DUAL ILT2/ILT4 ANTAGONIST ANTIBODY



Advanced Solid Tumors

Phase 1/2 Trial (Enrolling)

Monotherapy and Combination Therapy with KEYTRUDA® (pembrolizumab)

Advanced Solid Tumors

Phase 1/2 Trial (Enrolling)

Monotherapy and Combination Therapy with KEYTRUDA® (pembrolizumab)

NGM831
NGM831

ILT3 ANTAGONIST ANTIBODY



Advanced Solid Tumors

Phase 1a/1b Trial (Enrolling)

Monotherapy and Combination Therapy with KEYTRUDA

Advanced Solid Tumors

Phase 1a/1b Trial (Enrolling)

Monotherapy and Combination Therapy with KEYTRUDA

NGM438
NGM438

LAIR1 ANTAGONIST ANTIBODY



Advanced Solid Tumors

Phase 1a/1b Trial (Enrolling)

Monotherapy and Combination Therapy with KEYTRUDA

Advanced Solid Tumors

Phase 1a/1b Trial (Enrolling)

Monotherapy and Combination Therapy with KEYTRUDA

CANCER & CACHEXIA

NGM120
NGM120

GFRAL ANTAGONIST ANTIBODY



Advanced Solid Tumors

Phase 2 PINNACLES Trial (Enrolling Patients with Metastatic Pancreatic Cancer)

Phase 1a/1b Trial (Ongoing)

Advanced Solid Tumors

Phase 2 PINNACLES Trial (Enrolling Patients with Metastatic Pancreatic Cancer)

Phase 1a/1b Trial (Ongoing)


RETINAL DISEASES

NGM621
NGM621

ANTI-COMPLEMENT C3 ANTIBODY



Geographic Atrophy

Phase 2 CATALINA Trial (Enrollment completed)

Merck Right to Option at Proof-of-Concept

Geographic Atrophy

Phase 2 CATALINA Trial (Enrollment completed)

Merck Right to Option at Proof-of-Concept


LIVER & METABOLIC DISEASES

MK-3655
MK-3655

FGFR1C/KLB AGONISTIC ANTIBODY



NASH F2/F3

Phase 2b Trial (Enrolling)

Merck Optioned at Proof-of-Concept

NASH F2/F3

Phase 2b Trial (Enrolling)

Merck Optioned at Proof-of-Concept

Aldafermin
Aldafermin

FGF19 ANALOG



NASH F4

Phase 2b ALPINE 4 Trial (Enrollment completed)

NASH F4

Phase 2b ALPINE 4 Trial (Enrollment completed)

NGM'S DISCOVERY ENGINE

 * Approach
   
   
   BIOLOGY-LED INNOVATION
   
   
   
   NGM is built on a straightforward central premise: create an environment that
   allows drug discovery research to thrive by focusing on powerful human
   biology unconstrained by therapeutic area or technology approach. Regardless
   of where it leads us, our scientific exploration is grounded in a singular
   motivation: deliver important medicines to address critical unmet medical
   needs in grievous diseases. The heart and soul of NGM, our discovery engine
   fuels ongoing innovation and is the source of our diverse and growing
   pipeline of candidates.
   
   
   
   icon / arrow
   Learn More
   
 * Expertise
 * Output
 * Scientific Values


BIOLOGY-LED INNOVATION



NGM is built on a straightforward central premise: create an environment that
allows drug discovery research to thrive by focusing on powerful human biology
unconstrained by therapeutic area or technology approach. Regardless of where it
leads us, our scientific exploration is grounded in a singular motivation:
deliver important medicines to address critical unmet medical needs in grievous
diseases. The heart and soul of NGM, our discovery engine fuels ongoing
innovation and is the source of our diverse and growing pipeline of candidates.



icon / arrow
Learn More



BIOLOGICAL AND PROTEIN ENGINEERING EXPERTISE



We integrate deep expertise in experimental biology with leading capabilities in
protein and antibody engineering. This approach drives a synergy that allows us
to rapidly test multiple hypotheses, identify compelling targets and use the
resulting biological insights to engineer promising drug candidates.



icon / arrow
Learn More



BROAD AND DIVERSE PORTFOLIO



Our discovery engine has yielded a deep portfolio of drug candidates, currently
spanning oncology, retinal diseases and liver and metabolic diseases. Beyond our
disclosed programs, we have multiple research programs — all generated from our
discovery engine — vying to deliver our next clinical candidate.



icon / arrow
Learn More



PRINCIPLES AND PURPOSE



At NGM, science comes first. We pride ourselves on the daily pursuit of
excellence and a culture of scientific rigor that extends from our drug
discovery efforts through clinical development. Our scientific values ground and
guide us as we work together to explore complex biology and advance new
medicines for patients in need.



icon / arrow
Learn More



MEET OUR TEAM



We are explorers — 200+ strong. We are awed by human biology, undaunted by
difficult problems, committed to excellence, optimistic about what lies ahead
and humbled by the privilege and responsibility of discovering and developing
medicines for our fellow humans.



icon / arrow
Meet Our Team


CAREERS AT NGM

We are seeking fellow explorers with a pioneering spirit, a penchant to break
free from convention, an eagerness to contribute in meaningful ways, and an
innate desire to make a difference in the world through the advancement of
life-changing medicines.

Join Us
icon / →



BUILT FROM SCRATCH. LED BY BIOLOGY. MOTIVATED BY PATIENTS.

icon / arrow
Learn More
Group 3

Explorers on the frontier of life-changing science.


 * Careers
 * Contact
 * Terms of Use
 * Privacy Policy

twitter
instagram
linked in
© 2022 NGM Biopharmaceuticals. All Rights Reserved.


PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Back Button


PERFORMANCE COOKIES



Vendor Search Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Reject All Confirm My Choices


By clicking “Accept All Cookies”, you agree to the storing of cookies on your
device to enhance site navigation, assist in marketing efforts, and analyze site
usage.Read about cookies in our Privacy Policy.

Cookies Settings Reject All Accept All Cookies